Acute Leukemias V: Experimental Approaches and Management of Refractory Disease
Springer Berlin Heidelberg, Jan 17, 1996 - Medical - 613 pages
150 years after the first description of the clinical picture of "white blood" and the introduction of the term "leukemia" by R. Virchow it appears, that the leukemias, and the acute leukemias in particular, serve as an impressive example for the major improvements that have been achieved in the treatment but also in the understand ing of the biology of malignant dis orders. The international symposia "Acute Leukemia" which are held at Münster since 1986 have developed into an interna tional forum to review the current progress and the future perspectives of leukemia research and therapy at a high scientific and clinicallevel. Since the possibility for active participation in these symposia is somewhat restricted we are glad to have the opportunity to extend the information that was presented at the symposium "Acute Leukemias V - Experimental Approaches and Management of Refractory Disease" which was held from February 27 to March 2, 1994 to a broader audience of basic scientists and clinicians. This meeting was especiaIly designed to discuss experimen tal approaches and the management of refractory disease which allows to evaluate new experimental therapies on the basis of preclinical studies.
What people are saying - Write a review
We haven't found any reviews in the usual places.
A New Approach
Fludarabine and AraC Combination for Treatment of Adult Acute
Differential Effect of GMCSF on the Intracellular AraC Metabolism
22 other sections not shown
Other editions - View all
ABMT activity acute leukemia acute lymphoblastic leukemia acute myelogenous leukemia acute myeloid leukemia adult allogeneic allogeneic bone marrow AML patients analysis antigens apoptosis Approaches and Management Ara-C ara-CTP assay autologous Berlin Heidelberg 1996 blast cells bone marrow transplantation Cancer cell lines chemotherapy chromosome Clin clinical clonal clones complete remission cycles cytarabine cytogenetic cytokines cytotoxic daunorubicin detection diagnosis differentiation donor drug effect etoposide Experimental Approaches expression fludarabine gene GM-CSF granulocyte growth factors Haematol Hematology hematopoietic high-dose human idarubicin induction therapy infusion inhibition interleukin-2 Leukemias V Experimental leukemic cells lymphocytes lymphoma Management of Refractory median mg/m mitoxantrone months normal Oncol Oncology P-gp patients with acute patients with AML peripheral blood pharmacokinetic prognostic protein protocol receptor Refractory Diseases Hiddemann regimen relapse response Springer-Verlag Berlin Heidelberg stem cells survival Table tion toxicity translocation treated treatment tumor vitro vivo